President Biden tells Yahoo Finance that new China tariffs are about being 'fair'

NasdaqGS - Delayed Quote USD

Xilio Therapeutics, Inc. (XLO)

1.0900

-0.0300

(-2.68%)

At close: 4:00 PM EDT

1.1100

+0.02

(+1.83%)

After hours: 5:00 PM EDT

Key Events

Loading Chart for XLO

9/21 12:03 PM

DELL

Previous Close 1.1200
Open 1.0600
Bid 1.0500 x 100
Ask 1.1600 x 100
Day's Range 1.0600 - 1.1400
52 Week Range 0.4900 - 3.2500
Volume 125,287
Avg. Volume 1,262,357
Market Cap (intraday) 40.234M
Beta (5Y Monthly) -0.09
PE Ratio (TTM) --
EPS (TTM) -2.7800
Earnings Date Apr 1, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 5.50

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

73

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

XLO

98.18%

S&P 500

10.00%

1-Year Return

XLO

65.62%

S&P 500

27.22%

3-Year Return

XLO

--

S&P 500

15.44%

5-Year Return

XLO

--

S&P 500

15.44%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Xilio Therapeutics, Inc.

1.0900

-2.68%

Mkt Cap 40.234M

Industry Biotechnology

Sensei Biotherapeutics, Inc.

1.5100

-3.82%

Mkt Cap 37.872M

Industry Biotechnology

Rallybio Corporation

1.8400

+3.37%

Mkt Cap 76.267M

Industry Biotechnology

Biodexa Pharmaceuticals Plc

1.1000

+13.99%

Mkt Cap 4.824M

Industry Biotechnology

1.0400

+2.97%

Mkt Cap 45.889M

Industry Biotechnology

2.6100

-1.14%

Mkt Cap 125.557M

Industry Biotechnology

LAVA Therapeutics N.V.

2.8900

-5.56%

Mkt Cap 75.976M

Industry Biotechnology

PaxMedica, Inc.

0.2070

-9.53%

Mkt Cap 1.545M

Industry Biotechnology

CERo Therapeutics Holdings, Inc.

1.1355

-2.11%

Mkt Cap 16.719M

Industry Biotechnology

Phio Pharmaceuticals Corp.

0.7338

+6.66%

Mkt Cap 3.369M

Industry Biotechnology

NexImmune, Inc.

3.4000

-0.29%

Mkt Cap 4.662M

Industry Biotechnology

Valuation Measures

As of 5/13/2024

Market Cap

41.34M
Enterprise Value

9.14M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

1.12
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-49.44%
Return on Equity (ttm)

-107.25%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-76.4M
Diluted EPS (ttm)

-2.7800

Balance Sheet and Cash Flow

Total Cash (mrq)

44.7M
Total Debt/Equity (mrq)

34.08%
Levered Free Cash Flow (ttm)

-42.32M

XLO does not have Company Insights

CADL Candel Therapeutics, Inc.

10.70

+4.90%

TYRA Tyra Biosciences, Inc.

18.58

+0.43%

HOWL Werewolf Therapeutics, Inc.

4.9300

+10.54%

IMRX Immuneering Corporation

1.6000

+0.63%

RLYB Rallybio Corporation

1.8400

+3.37%

TNYA Tenaya Therapeutics, Inc.

4.4000

+2.80%

LVTX LAVA Therapeutics N.V.

2.8900

-5.56%

INAB IN8bio, Inc.

1.0400

+2.97%

VINC Vincerx Pharma, Inc.

0.7646

+1.18%

BDRX Biodexa Pharmaceuticals Plc

1.1000

+13.99%

VTYX Ventyx Biosciences, Inc.

4.1700

+1.21%

AVTX Avalo Therapeutics, Inc.

10.60

-2.03%

VIGL Vigil Neuroscience, Inc.

3.6600

+0.27%

ELYM Eliem Therapeutics, Inc.

8.19

-2.62%

RPHM Reneo Pharmaceuticals, Inc.

1.6200

+1.89%

ELEV Elevation Oncology, Inc.

3.5600

+0.56%